Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN107,9108,2-1,92
Msft-0,13
Nokia5,8665,921,16
IBM1,10
Mercedes-Benz Group AG57,5857,60,89
PFE0,40
14.02.2026 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 13.02.2026
Innovotech (Canada Venture Exchange)
Závěr k 13.2.2026 Změna (%) Změna (CAD) Objem obchodů (CAD)
0,235 0,00 0,00 -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 15.02.2026
Popis společnosti
Obecné informace
Název společnostiInnovotech Inc
TickerIOT
Kmenové akcie:Ordinary Shares
RICIOT.V
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky30.09.2025
Počet zaměstnanců k 13.03.2012 16
Akcie v oběhu k 08.12.2025 54 438 232
MěnaCAD
Kontaktní informace
Ulice2011 94 St NW Suite 101
MěstoEDMONTON
PSČT6N 1H1
ZeměCanada
Kontatní osoba 
Funkce kontaktní osoby 
Telefon17 804 480 585
Fax17804240941

Business Summary: Innovotech Inc. is a diversified Canadian technology company with business operations in a portfolio of specialized laboratory services, biotechnology businesses, and proprietary intellectual property. Innovotech Labs Corporation, a wholly owned subsidiary, is a contract research organization that owns and provides proprietary devices for antimicrobial testing in multiple applications and commercializes antimicrobial silver solutions. Its operating company, Keystone Labs Inc. is a lab serving the Canadian pharmaceutical industry and industrial markets. The Company has offerings in antimicrobial contract services and is the vendor for several global medical device companies. It owns a 60% interest in Noulife Sciences Inc., a company that owns intellectual property for linked antioxidant molecules commonly used in skin care and in the treatment of certain medical conditions. It also manufactures and sells several types of laboratory consumables. It manages several subsidiary companies.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Innovotech Inc revenues increased from C$1.1M to C$3.4M. Net loss decreased 67% to C$80K. Revenues reflect Canada segment increase from C$82K to C$843K. Lower net loss reflects Fair value changes increase from C$4K to C$98K (income), Grants and tax credits increase of 60% to C$202K (income).
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSIn-Vitro Diagnostic Substance Manufacturing
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSSoil Preparation, Planting, and Cultivating
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007In-Vitro Diagnostic Substance Mfg
NAICS2007Electromedical Apparatus Mfg
NAICS2007Soil Preparation, Planting, & Cultivating
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997InVitro Diagnostic Substance Manufacturing
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
NAICS1997Soil Preparation, Planting, and Cultivating
SICCommercial Physical Research
SICDiagnostic Substances
SICElectromedical Equipment
SICSoil Preparation Services



  • Poslední aktualizace: 15.02.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the Board, Company SecretaryJames Timourian-01.08.2023
Chief Executive Officer, DirectorCraig Milne-01.08.202301.08.2023
Chief Financial OfficerBernard Grobbelaar-12.12.202325.03.2014
Chief Operating OfficerJodi McDonald-01.02.202601.02.2026